Spectral Medical Inc. provided an update on the Company?s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (?PMX?) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Initiated 2024 with robust site activity to start the new year: Enrolled patient 82 during the first week of January. Post-holiday break, strong screening activity resumed with more than 100 patients screened per week.

Closing in on the interim enrollment target of 90 patients (?Interim Enrollment?); at Interim Enrollment, Baxter International (NYSE.BAX) has the option to make the second non-dilutive milestone payment to Spectral to maintain its PMX exclusive distribution rights. Crude mortality results at both 28-day (primary endpoint) and at one year, thus far, continue to exceed efficacy targets. Trial Sites: Near term onboarding of six new, high quality clinical sites.

Expect significant site onboarding activity during the first quarter of 2024.